These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18370448)

  • 21. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
    Croft H; Settle E; Houser T; Batey SR; Donahue RM; Ascher JA
    Clin Ther; 1999 Apr; 21(4):643-58. PubMed ID: 10363731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spotlight on escitalopram in the management of major depressive disorder.
    Murdoch D; Keam SJ
    CNS Drugs; 2006; 20(2):167-70. PubMed ID: 16478291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of sexual dysfunction among newer antidepressants.
    Clayton AH; Pradko JF; Croft HA; Montano CB; Leadbetter RA; Bolden-Watson C; Bass KI; Donahue RM; Jamerson BD; Metz A
    J Clin Psychiatry; 2002 Apr; 63(4):357-66. PubMed ID: 12000211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of bupropion in combination with serotonin reuptake inhibitors.
    Zisook S; Rush AJ; Haight BR; Clines DC; Rockett CB
    Biol Psychiatry; 2006 Feb; 59(3):203-10. PubMed ID: 16165100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder.
    Fagiolini A; Cardoner N; Pirildar S; Ittsakul P; Ng B; Duailibi K; El Hindy N
    Expert Opin Pharmacother; 2023; 24(15):1715-1723. PubMed ID: 37501324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
    Maneeton N; Maneeton B; Eurviriyanukul K; Srisurapanont M
    Drug Des Devel Ther; 2013; 7():1053-62. PubMed ID: 24101861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
    Coleman CC; King BR; Bolden-Watson C; Book MJ; Segraves RT; Richard N; Ascher J; Batey S; Jamerson B; Metz A
    Clin Ther; 2001 Jul; 23(7):1040-58. PubMed ID: 11519769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
    Malone DC
    J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to bupropion in fluoxetine-resistant major depressive disorder.
    Fava M; Papakostas GI; Petersen T; Mahal Y; Quitkin F; Stewart J; McGrath P
    Ann Clin Psychiatry; 2003 Mar; 15(1):17-22. PubMed ID: 12839429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.
    Jha MK; Minhajuddin A; Gadad BS; Greer TL; Mayes TL; Trivedi MH
    Brain Behav Immun; 2017 Nov; 66():103-110. PubMed ID: 28698115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.